Is Entero Healthcar overvalued or undervalued?

As of 12 September 2025, Entero Healthcare's valuation grade has moved from attractive to very attractive. The company is currently assessed as undervalued. Key ratios include a PE ratio of 49.01, an EV to EBITDA of 26.60, and a PEG ratio of 0.34, which indicates strong growth potential relative to its price. In comparison to peers, Entero Healthcare's PE ratio significantly exceeds that of TCS at 23.01 and Infosys at 23.24, while its EV to EBITDA is higher than TCS's 16.22 but lower than LTI Mindtree's 22.84. Despite its recent stock performance lagging behind the Sensex, with a year-to-date return of -18.35% compared to the Sensex's 4.82%, the underlying valuation metrics suggest that Entero Healthcare presents a compelling investment opportunity.